Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Eli Lilly Corp.

Start price
Target price
Perf. (%)
€526.00
14.12.23
€558.00
14.12.24
0.57%
18.12.23

Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€568.50
11.10.23
€558.00
11.10.24
-7.48%
14.12.23

Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
buy
Fresenius Medical Care AG & Co KGaA ST

Start price
Target price
Perf. (%)
€33.12
11.10.23
-
11.10.24
14.79%
12.12.23

Known brand
Could be worthwhile Investment >10% per year
buy
AbbVie Inc.

Start price
Target price
Perf. (%)
€156.72
09.12.22
-
09.12.23
-11.18%
10.12.23

buy
Bayer AG

Start price
Target price
Perf. (%)
€31.93
08.12.23
-
08.12.24
0.11%
08.12.23

Could be very worthwhile Investment >20% year
buy
Bayer AG

Start price
Target price
Perf. (%)
€34.23
20.11.23
€42.00
20.11.24
-6.50%
07.12.23

Undervalued
Well known brand
Future proof or reliable business model
Top 10 in its market
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€75.86
04.11.23
€89.00
04.12.23
-4.82%
05.12.23

Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Bayer AG

Start price
Target price
Perf. (%)
€32.77
24.11.23
€35.00
21.12.23
-6.78%
29.11.23

Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
buy
Exact Sciences

Start price
Target price
Perf. (%)
€55.41
11.11.23
€105.00
11.12.23
7.56%
25.11.23

Revenue growth >5% per year expected
Rising EBIT margin expected
Standard Investments for future growth
negative Cash Flow expected
buy
Bayer AG

Start price
Target price
Perf. (%)
€33.84
21.11.23
€35.00
21.12.23
-3.16%
24.11.23

Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Bayer AG

Start price
Target price
Perf. (%)
€40.83
15.11.23
€35.00
15.11.24
-19.02%
22.11.23

Probably not worthwhile Investment
Higher risks for its business
buy
Bayer AG

Start price
Target price
Perf. (%)
€52.39
07.08.23
€54.00
07.08.24
-35.42%
21.11.23

Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
buy
Bayer AG

Start price
Target price
Perf. (%)
€40.81
31.10.23
-
31.10.24
-18.31%
20.11.23

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Growths faster than the competition
Significant cyclical dependencies
buy
Teva Pharmaceutical Industries Ltd ADR

Start price
Target price
Perf. (%)
€7.68
23.10.23
-
23.10.24
10.16%
06.11.23

Top 10 in its market
Future proof or reliable business model
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€370.05
04.11.22
€610.00
04.11.23
44.17%
05.11.23

Top 10 in its market
Could be worthwhile Investment >10% per year
High dividend yield expected
Innovative
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€107.85
29.10.23
€150.00
31.03.26
-
30.10.23

Could be very worthwhile Investment >20% year
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€67.38
13.10.22
€46.00
13.10.23
9.44%
14.10.23

Top 10 in its market
Good rating
Medium risks for its business
Bad culture
buy
GSK plc

Start price
Target price
Perf. (%)
€15.62
13.10.22
€20.00
13.10.23
11.01%
14.10.23

High dividend yield expected
Good rating
Very small cyclical dependencies
Fair valuation
Fresenius Medical Care AG & Co KGaA ST

Start price
Target price
Perf. (%)
€38.99
04.10.23
€22.00
04.10.24
-16.75%
14.10.23

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€533.50
19.09.23
€558.00
19.09.24
6.56%
11.10.23

Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
buy
Illumina Inc.

Start price
Target price
Perf. (%)
€219.65
06.10.22
-
06.10.23
-39.65%
06.10.23

buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€422.40
27.06.23
€800.00
31.01.29
20.50%
01.10.23

Could be very worthwhile Investment >20% year
buy
Amgen Inc.

Start price
Target price
Perf. (%)
€246.80
19.09.23
€250.00
19.09.24
4.13%
27.09.23

Could be worthwhile Investment >10% per year
High dividend yield expected
positive Cash Flow expected
Good rating
Novartis AG ADR

Start price
Target price
Perf. (%)
€79.40
21.09.22
€70.00
21.09.23
20.40%
22.09.23

buy
Amgen Inc.

Start price
Target price
Perf. (%)
€228.00
20.09.22
€270.00
20.09.23
11.84%
21.09.23